@icosociety.bsky.socialIt's official: GC-OS is heading to Tokyo in 2027 🇯🇵
Want to be the first to know about updates for #GCOS27? Join our mailing list 👇
#GCOS27 #CardioOncology #CardioOnc #Tokyo #Japan #CardioOncologyConference #HealthcareConference
@icosociety.bsky.socialAfter lunch at #GCOS26: the IC-OS Champions League Final is on! 🏆
Who takes home the silverware and the title of cardio-oncology knowledge champs? Then we explore the cardiovascular challenges facing cancer survivors post-treatment.
@icosociety.bsky.socialUp Next at #GCOS26 👀
Our second amyloidosis session on the latest treatments, then a conversation on cardiotoxicity from new-generation cancer therapies. Lunch follows, with the product theatre sponsored by @Alnylam 🍽️
@icosociety.bsky.social#GCOS26 Day 2 starts now! 🫀
Today: exercise and cardio-oncology, amyloidosis, and limiting cardiotoxicity. See you in the Virginia Room at 8:00 AM.
@icosociety.bsky.socialWelcome back from lunch! 👋
Afternoon at #GCOS26 starts with our first Amyloidosis session on diagnosis and clinical case studies.
Then, 2026 #ThomasForceAward winner Dr. Alex Lyon 🇬🇧 presents "Ten Laws of Cardio-Oncology."
@icosociety.bsky.socialThat's a wrap on the meeting portion of Day 1 at #GCOS26! 👏
But we're not through yet – join us for our poster session, followed by dinner in the Colony Room (tickets required). 🍽️
#GCOS26 #CardioOncology #CardioOnc #CardioOncologyConference #WilliamsburgVA
@icosociety.bsky.socialEric Harrison, MD: IC-OS Board Member, cardiac imaging pioneer, and founder of Cardio-Orthopaedics.
Today at #GCOS26, we honor his legacy by inducting him into the IC-OS Hall of Fame. 🏅
Learn more: ic-os.org/HOF2026
@icosociety.bsky.socialCongrats again to Dr Alexander Lyon, your 2026 Thomas Force Award Winner!
#GCOS26 #GCOS2026 #GCOS #ThomasForce #ThomasForceAward #CardioOncology #CardioOnc #CancerCare #CancerTreatment
@icosociety.bsky.socialAfter the break at #GCOS26 ⏭️
📊 IC-OS leaders on the year's progress
🏅 Our newest IC-OS Hall of Fame inductee
🌟 The Young Investigator Awards
@icosociety.bsky.social
@icosociety.bsky.socialUp Next at #GCOS26 👀
Late morning kicks off with a discussion on how AI is changing cardio-oncology – followed by the year's best research. Then it's lunch and a tour of the product theatre with sponsor @AstraZeneca.
@icosociety.bsky.socialPatients are the reason we are all here for #GCOS26 ❤️
Cardio-oncology patient Tara Daudani is here with us today to share her perspective on how cardio-oncology has impacted her life.
Thank you Tara for sharing your story!
@icosociety.bsky.social@icosociety.bsky.social#GCOS26 is officially here! 🤩
A full day of global insights and networking starts at 8am sharp. Grab a coffee and get acquainted with the schedule 👇
@icosociety.bsky.social
@medliveofficial.bsky.socialHow can ADT strategies impact CV outcomes in prostate cancer? Explore case-based guidance on CV risk assessment, treatment selection, monitoring, and multidisciplinary care.
▶️ Access on-demand: vist.ly/5hr45
@aspcardio.bsky.socialLearn how ADT strategies impact cardiovascular outcomes in prostate cancer patients through expert case discussions. ▶️ Watch: https://bit.ly/4cwo6xg #ProstateCancer #CardiovascularHealth #CardioOncology #MedicalEducation
@icosociety.bsky.socialDuring #cancer treatment, Jackie Ellis appeared to develop ICI myocarditis.
This week on #HeartToHeart, she & cardio-oncologist Josh Mitchell, MD share how #oncology-#cardiology teamwork kept her care on track.
@j-cardio-oncol.bsky.socialNew systematic review & meta-analysis: PD-1/PD-L1 inhibitor combos vs controls raise CV adverse event risk, highest in targeted combos, with elevated risk in lung, multiple myeloma, urothelial and head/neck cancer patients. #CardioOncology #ImmunoOncology https://doi.org/10.1097/co9.0000000000000021